studies

1208A AASLD ABSTRACTS HEPATOLOGY, October, 2015
CLUSION: The baseline HBV DNA level and the duration of
consolidation therapy in inactive carriers were indicators for
SOVR after stopping preemptive AVT.
Disclosures:
The following authors have nothing to disclose: Seung Hyeon Jang, Hyo Jin Kim,
jung hee kim, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok
Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
2050
Prediction of sustained off-treatment response in chronic
hepatitis B patients undergoing pegylated interferon
treatment by a new scoring model
Yin-Chen Wang 1 , Yi-Hsiang Huang 1,3 , Sien-Sing Yang 2 , Chien-
Wei Su 1 , Kuei-Chuan Lee 1 , Han-Chieh Lin 1 ; 1 Taipei Veterans
General Hospital, Division of Gastroenterology, Department of
Medicine, Taipei City, Taiwan; 2 Cathay General Hospital Medical
Center, Liver Center, Taipei, Taiwan; 3 National Yang-Ming University,
Institute of Clinical Medicine, Taipei, Taiwan
Background The pegylated interferon-α-2a (PEG-IFN-α2a) is
one of the first line treatment options for chronic hepatitis B
(CHB). However, the overall response rate is not satisfactory
mainly due to the lack of a practical model to select patients
who would have the best chance of response. The aim of this
study was to develop a new simple scoring model to predict sustained
off-treatment response of PEG-IFN-α2a in CHB patients.
Methods We retrospectively reviewed consecutive 201 CHB
patients who underwent PEG-IFN-α2a treatment from Taipei
Veterans General Hospital and Cathay General Hospital. Of
them, 118 were hepatitis B e antigen (HBeAg)-positive and 83
were HBeAg-negative. Sustained off-treatment response was
defined as HBeAg seroconversion in accompanied with HBV
DNA less than 2,000 IU/ml at 48 weeks post treatment for
HBeAg-positive patients, and HBV DNA less than 2,000 IU/ml
at 48 weeks post treatment for HBeAg-positive patients. Multivariate
Logistic regression was performed to determine factors
associated with the response. Results For HBeAg-positive CHB
patients, baseline hepatitis B s antigen (HBsAg) 5 ULN CK elevation and progressive
muscular symptoms, it was planned to evaluate the course of
treatment to stop or to go on. Results Total 178 patients (105
male, 73 female) were included to the study. Mean age was
39.9±11.4 year (17-72 years) and mean duration of therapy
25 months (6-40 months). Mean serum CK level at the admission
was 133±106 U/L (34-823 U/L). In 66 patients (37%)
CK level was remained normal throughout the treatment. The
highest level of CK was 2221 U/L during the treatment. Significant
elevation of CK levels were observed after ninth month of
therapy (p